Market Overview - US stock indices rebounded, influenced positively by Trump's market support, leading to a 0.68% rise in Hong Kong stocks [1] - San Francisco Fed President Daly indicated that the timing for interest rate cuts is approaching, with expectations for two 25 basis point cuts this year [1] - Goldman Sachs predicts three consecutive 25 basis point cuts starting in September, with a potential 50 basis point cut if unemployment rises further [1] Domestic Market Sentiment - A-share new account openings in July reached 1.96 million, a 71% year-on-year increase, indicating rising domestic confidence [2] - The stock of Upwind New Materials surged 20% after resuming trading, reigniting market enthusiasm [2] - The steel sector saw a significant rise, with Maanshan Iron & Steel's stock increasing over 15% due to improved loss forecasts and supportive policies [2] Industry Trends - The paper industry is experiencing a price increase, with major companies like Nine Dragons Paper and Lee & Man Paper announcing price hikes [2] - The eleventh batch of centralized drug procurement in China saw a record 45 companies applying for the same drug, intensifying competition in the generic drug market [3] - Investment is shifting towards innovative drugs, with companies like Junshi Biosciences seeing stock increases of nearly 34% due to promising clinical trials [3] Financial Support for Key Industries - A joint guideline from the central bank and seven departments aims to support financing for key manufacturing sectors, including integrated circuits and medical equipment [4] - AI-related companies like Longi Green Energy and Lenovo's server business are seeing stock increases due to new orders and market interest [4] Gaming Industry Performance - The domestic gaming market is projected to reach RMB 168 billion in sales by the first half of 2025, a 14.08% year-on-year increase [4] - Heartbeat Games anticipates a revenue increase of approximately 37% for the first half of 2025, driven by strong performance from self-developed games [4] Individual Company Highlights - Tencent's mobile game "Valorant: Source Action" is set to launch on August 19, with projected annual revenue exceeding RMB 6 billion [5] - Oriental Selection's stock surged nearly 17% ahead of its upcoming financial report, reflecting strong market performance [6] - The Macau gaming sector is experiencing a positive trend, with Morgan Stanley raising its revenue growth forecast for the year from 5% to 10% [6] Technological Advancements - Apple's breakthrough in brain-computer interface (BCI) technology allows users to control devices through thought, indicating a significant market opportunity [7] - The Chinese BCI market is expected to exceed RMB 3.8 billion by 2025, with a CAGR of approximately 20% [7] Investment Opportunities - Kelun-Bio has become a top holding in a major fund, indicating strong market confidence in its innovative drug pipeline [8] - The company has established multiple technology platforms and is expected to accelerate commercialization in 2025 [8]

Market Overview - On August 5, the Hang Seng Index rose by 0.68%, with total southbound trading amounting to HKD 129.701 billion, including buy transactions of HKD 76.563 billion and sell transactions of HKD 53.138 billion, resulting in a net buy of HKD 23.426 billion [1] Southbound Trading Details - The southbound trading through Stock Connect (Shenzhen) had a total trading amount of HKD 47.198 billion, with buy transactions of HKD 28.343 billion and sell transactions of HKD 18.854 billion, leading to a net buy of HKD 9.489 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading amount of HKD 82.504 billion, with buy transactions of HKD 48.220 billion and sell transactions of HKD 34.284 billion, resulting in a net buy of HKD 13.936 billion [1] Active Stocks - The most actively traded stock by southbound funds was the Tracker Fund of Hong Kong, with a total trading amount of HKD 6.3006 billion and a net buy of HKD 6.2929 billion, closing with a price increase of 0.63% [1] - Tencent Holdings and SMIC followed, with trading amounts of HKD 4.898 billion and HKD 3.569 billion, respectively [1] - A total of 12 stocks experienced net buying, with Tencent Holdings seeing a net buy of HKD 0.832 billion and Southern Hang Seng Technology a net buy of HKD 0.798 billion [1] Continuous Net Buying - Among the stocks, Tencent Holdings, Xiaomi Group-W, and Kuaishou-W were continuously net bought for more than three days, with Tencent Holdings leading with a total net buy of HKD 4.426 billion over nine days [2] - Xiaomi Group-W followed closely with a net buy of HKD 4.411 billion over eight days, and Kuaishou-W with HKD 2.452 billion over four days [2] Summary of Active Stocks on August 5 - The following table summarizes the active stocks and their respective trading amounts, net buying, and daily price changes: | Code | Name | Trading Amount (HKD million) | Net Buy (HKD million) | Daily Change (%) | |--------|--------------------|------------------------------|-----------------------|-------------------| | 02800 | Tracker Fund | 6300.64 | 6292.99 | 0.63 | | 00700 | Tencent Holdings | 4897.79 | 831.72 | 1.64 | | 03033 | Southern Hang Seng Tech | 868.05 | 798.36 | 0.93 | | 01024 | Kuaishou-W | 2408.49 | 646.71 | 2.79 | | 02015 | Li Auto-W | 2927.53 | 586.03 | 1.58 | | 09988 | Alibaba-W | 3391.32 | 511.50 | -0.17 | | 01357 | Meituan | 2976.58 | 386.43 | -6.92 | | 09926 | CanSino Biologics | 877.47 | 290.20 | 7.17 | | 03690 | Meituan-W | 901.74 | 270.26 | -0.08 | | 01810 | Xiaomi Group-W | 2887.14 | 248.22 | -0.46 | | 02577 | InnoCare Pharma | 2303.82 | 232.89 | -6.65 | | 00981 | SMIC | 3568.78 | 121.27 | -0.97 | | 01788 | Guotai Junan International | 2225.67 | -5.07 | -0.94 | [2]

Core Viewpoint - The Hong Kong stock market is experiencing a strong performance, particularly in the innovative pharmaceutical sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) leading the gains, reflecting a growing interest and activity in this industry [1][6]. Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened strong and rose by 2.73%, closing above the 5-day moving average with a trading volume exceeding 800 million yuan [1][2]. - Among the 30 constituent stocks in the innovative drug sector, 22 stocks increased by over 2%, with notable gains from companies like Lepu Biopharma-B, Ascentage Pharma-B, and CanSino Biologics-B, which saw double-digit increases [1][4]. Key Stocks - Kangfang Biotech surged over 7%, reaching a historical high, following the initiation of a global Phase III clinical trial for its dual-target drug, Ivosidenib [3]. - Innovent Biologics rose over 6%, benefiting from a report by JPMorgan highlighting the importance of business development (BD) in the biopharmaceutical sector this year [3]. - 3SBio Inc. increased by 5.97%, with recent announcements regarding a share placement to Pfizer, raising approximately 785 million HKD for clinical and preclinical projects [3]. Industry Growth - The National Medical Products Administration reported that 43 innovative drugs were approved in the first half of the year, a 59% increase year-on-year, nearing the total of 48 approvals expected for the entire year of 2024 [4]. - The innovative drug sector is entering a phase of significant technological advancements, with domestic companies increasingly leading innovation rather than merely following trends [5]. Policy Support - Recent favorable policies from the National Healthcare Security Administration include a price stabilization mechanism for newly launched drugs, which aims to prevent immediate price reductions upon market entry [5]. - Analysts from China International Capital Corporation express optimism about the long-term development of the innovative drug industry, supported by a favorable regulatory environment and abundant clinical resources [5]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the first ETF to track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain [6]. - Year-to-date, the index has increased by 101.58%, significantly outperforming the Hang Seng Index and the Hang Seng Tech Index [8].

深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 腾讯控股(00700) | 19.54 亿元 | +3.05 亿元 | | 小米集团-W(01810) | 13.14 亿元 | +244.56 万元 | | 中芯国际(00981) | 12.65 亿元 | +2.74 亿元 | | 理想汽车-W(02015) | 12.52 亿元 | +3.00 亿元 | | 阿里巴巴-W(09988) | 12.19 亿元 | +2.55 亿元 | | 美图公司(01357) | 11.05 亿元 | +2.67 亿元 | | 快手-W(01024) | 9.07 亿元 | +3.05 亿元 | | 美团-W(03690) | 9.02 亿元 | +2.70 亿元 | | 康方生物(09926) | 8.77 亿元 | +2.90 亿元 | | 南方恒生科技(03033) | 8.68 亿元 | +7.98 亿元 | 智通财经APP获悉，2025年8月5日当天，盈富基金(02800)、腾讯控股(00700)、英诺赛科(02577)位居沪 港通（南向） ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, indicating a positive sentiment among investors towards certain stocks and sectors, particularly technology and ETFs [1][6]. Group 1: Northbound Trading Activity - Northbound trading recorded a net buy of HKD 234.26 billion, with HKD 139.36 billion from the Shanghai Stock Connect and HKD 94.89 billion from the Shenzhen Stock Connect [1]. - The most purchased stocks included the Tracker Fund of Hong Kong (盈富基金, 02800), Tencent (00700), and the Southern Hang Seng Technology ETF (南方恒生科技, 03033) [1][6]. - The stock with the highest net sell was Guotai Junan International (国泰君安国际, 01788), with a net outflow of HKD 50.72 million [1][9]. Group 2: Individual Stock Performance - The Tracker Fund of Hong Kong (02800) saw a net inflow of HKD 62.93 billion, while Tencent (00700) had a net inflow of HKD 5.26 billion [2]. - Other notable net inflows included InnoCare Pharma (英诺赛科, 02577) with HKD 2.33 billion, and Alibaba (阿里巴巴-W, 09988) with HKD 2.57 billion [2][8]. - Li Auto (理想汽车-W, 02015) received a net inflow of HKD 5.86 billion following an announcement of configuration adjustments for its i8 model [7]. Group 3: Sector Insights - The technology sector, which constitutes nearly one-third of the Hong Kong market, is expected to undergo a revaluation driven by improving fundamentals and policy expectations [6]. - Companies like Meitu (美图公司, 01357) reported a projected net profit increase of 65% to 72% year-on-year, indicating strong operational performance [7]. - UBS highlighted the potential of Akeso's core product AK112 in various cancer treatments, projecting significant revenue contributions from upcoming clinical trials [8].

Group 1 - Southbound funds recorded a net purchase of HKD 23.426 billion in Hong Kong stocks, marking the highest single-day net purchase since March 12 of this year [1] - The top net purchases included: - HKD 6.293 billion in the Tracker Fund of Hong Kong - HKD 0.831 billion in Tencent Holdings - HKD 0.798 billion in Southern Hang Seng Technology - HKD 0.646 billion in Kuaishou-W - HKD 0.586 billion in Li Auto-W - HKD 0.511 billion in Alibaba-W - HKD 0.386 billion in Meitu - HKD 0.290 billion in CanSino Biologics - HKD 0.270 billion in Meituan-W - HKD 0.248 billion in Xiaomi Group-W - HKD 0.232 billion in Innovent Biologics - HKD 0.121 billion in SMIC [1] Group 2 - Southbound funds have net purchased Tencent for 9 consecutive days, totaling HKD 4.426 billion - Southbound funds have net purchased Xiaomi for 8 consecutive days, totaling HKD 4.410 billion - Southbound funds have net purchased Kuaishou for 4 consecutive days, totaling HKD 2.452 billion [1]

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明 示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com | | 了成道 | | | | | --- | --- | --- | --- | --- | | 名称 | 涨跌幅 | 浄买入额(亿) | 成交额 | 名称 | | 盈富長金 | 0.6% | 62.93 | 63.00亿 | 腾讯控股 | | 腾讯控股 | 1.6% | 5.26 | 29.44亿 | 小米集团-W | | 英诺赛科 | -6.7% | 2.33 | 23.04亿 | 中芯国际 | | 中心国际 | -1.0% | -1.53 | 23.03亿 | 理想汽车-W | | 国泰君安国际 | -0.9% | -0.51 | 22.26亿 | 阿里巴巴-W | | 阿里巴巴-W | -0.2% | 2.57 | 21.72亿 | 美图公司 | | 美图公司 | -6.9% | 1.19 | 18.72亿 | 快手-W | | 理想汽车-W | 1 ...

Group 1 - The core viewpoint is that the liquidity and fundamentals of the Chinese healthcare industry continue to improve, maintaining a positive outlook for the healthcare sector [1] - The report indicates that the weak U.S. employment data may lead to heightened expectations for monetary easing in the second half of the year, suggesting an improved outlook for the industry [1] - The report highlights that the industry fundamentals are recovering, with a month-on-month increase in hospital prescription volumes in July, and significant profit growth expected in the third quarter due to the release of more innovative drugs [1] Group 2 - The company prefers leading large pharmaceutical firms and suggests avoiding companies overly reliant on biosimilars in the short term [2] - Selected stocks include: CSPC Pharmaceutical Group (01093), Sinopharm Group (01099), Hansoh Pharmaceutical (03692), and others [2] - The report emphasizes that the uncertainty in U.S. Treasury yields may prompt a reallocation of funds, further improving the liquidity of innovative drug assets [1]

里昂指出，行业基本面持续复苏，7月院内处方量环比提升，随着更多创新药放量，第三季行业盈利有 望实现显著增长，加上美债不确定性可能促使资金重新配置，进一步改善创新药资产流动性，相信行业 拐点已过，未来将迎来盈喜等正面催化剂。 该行偏好领先大型药厂，短期而言避开过度依赖生物仿制药的公司。该行选股包括石药集团(01093)、 新诺威(300765.SZ)、翰森制药(03692)、爱尔眼科(300015.SZ)、恒瑞医药(01276,600276.SH)、康方生物 (09926)、中生制药(01177)、国药控股(01099)、康哲药业(00867)、大参林(603233.SH)、华东医药 (000963.SZ)、泰格医药(03347)及药明康德(02359)。 智通财经APP获悉，里昂发布研报称，中国医疗健康行业流动性及基本面持续改善，维持对医疗健康板 块正面看法，指出美国就业数据疲软或市场对下半年货币宽松预期急升温，预示着行业下半年改善前 景，相信特朗普再提最惠国药品定价政策及安徽启动生物类似药集中采购，对行业影响则相对有限。 ...

Group 1 - The top three stocks with net inflows of southbound funds are Yingfu Fund (02800) with 2.858 billion, Hang Seng China Enterprises (02828) with 2.255 billion, and Meituan-W (03690) with 1.397 billion [1][2] - The top three stocks with net outflows of southbound funds are Pop Mart (09992) with -0.382 billion, Ping An of China (02318) with -0.360 billion, and Laopu Gold (06181) with -0.345 billion [1][2] - In terms of net inflow ratio, the top three are Hopson Development Holdings (00754) at 70.43%, K Wah International Holdings (00173) at 64.10%, and Qingdao Port International (06198) at 61.26% [1][2] Group 2 - The top three stocks with the highest net outflow ratios are Gawei Electronics (01415) at -60.55%, Bank of China Aviation Leasing (02588) at -46.75%, and GX Hengsheng Technology (02837) at -43.69% [1][3] - The top ten stocks with the highest net inflows include Kuaishou-W (01024) with 1.391 billion and Alibaba-W (09988) with 1.040 billion [2] - The top ten stocks with the highest net outflows also include CICC (03908) with -0.333 billion and Kangfang Biologics (09926) with -0.263 billion [2]